Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma

Endocrine-Related Cancer

Volumn 21, Issue 3, 2014, Pages 405-414

  Kimura, Noriko ^a   Takayanagi, Ryoichi ^b   Takizawa, Nae ^c   Itagaki, Eiji ^d   Katabami, Takayuki ^e   Kakoi, Narihiko ^f   Rakugi, Hiromi ^g   Ikeda, Yukihiro ^h   Tanabe, Akiyo ⁱ   Nigawara, Takeshi ^j   Ito, Sadayoshi ^k   Kimura, Itaru ^l   Naruse, Mitsuhide ^m  

^a Hakodate Medical Association Hospital   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KANSAI MEDICAL UNIVERSITY   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Miyagi Cancer Center   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h NIHON UNIVERSITY   (Japan)

ⁱ TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^j HIROSAKI UNIVERSITY   (Japan)

^k TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l Japan Ministry of Health Labour and Welfare   (Japan)

^m NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

more..

Author keywords

Histopathological diagnosis; Immunohistochemistry; Metastasis; Paraganglioma; Phaeochromocytoma; Succinate dehydrogenase gene subunit B; Survival

Indexed keywords

CATECHOLAMINE; KI 67 ANTIGEN; TUMOR MARKER; SDHB PROTEIN, HUMAN; SUCCINATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RELIABILITY; SDHB GENE; TUMOR DIFFERENTIATION; TUMOR INVASION; ADRENAL TUMOR; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CATECHOLAMINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROGNOSIS; SUCCINATE DEHYDROGENASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84903632940     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0494     Document Type: Article

References (27)

1. August C, August K, Schroeder S, Bahn H, Hinze R, Baba HA, Kersting C & Buerger H 2004 CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Modern Pathology 17 1119-1128. (doi:10.1038/modpathol.3800160)
2. Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S, Darrouzet V, Niccoli P, Gaillard D, Chabrier G, Chabolle F et al. 2009 The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. Journal of Clinical Endocrinology and Metabolism 94 2817-2827. (doi:10.1210/jc.2008-2504)
3. Castro-Vega LJ, Buffet A, De Cubas AA, Cascón A, Menara M, Khalifa E, Amar L, Azriel S, Bourdeau I, Chabre O et al. 2014 Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics [in press]. (doi:10.1093/hmg/ddt639)
4. Chrisoulidou A, Kaltsas G, Ilias I & Grossman AB 2007 The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocrine-Related Cancer 14 569-585. (doi:10.1677/ERC-07-0074) (Pubitemid 350074048)
5. Elder EE, Xu D, Höög A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C & BäckdahlM2003 KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Modern Pathology 16 246-255. (doi:10.1097/01.MP.0000056982.07160.E3) (Pubitemid 36337431)
6. Eisenhofer G, Lenders JW, Siegert G, Bornstein SR, Friberg P, Milosevic D, Mannelli M, Linehan WM, Adams K, Timmers HJ et al. 2012 Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumor size, location and SDHB mutation status. European Journal of Cancer 48 1739-1749. (doi:10.1016/j.ejca.2011.07.016)
7. Gimenez-Roqueplo AP & Tischler AS 2012 Pheochromocytoma and paraganglioma: progress on all fronts. Endocrine Pathology 23 1-3. (doi:10.1007/s12022-011-9190-7)
8. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X et al. 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research 63 5615-5621. (Pubitemid 37139886)
9. van der Harst E, Bruining HA, Jaap Bonjer H, van der Ham F, Dinjens WN, Lamberts SW, de Herder WW, Koper JW, Stijnen T, Proye C et al. 2000 Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? Journal of Pathology 191 175-180. (doi:10.1002/(SICI)1096- 9896(200006)191:2〈175::AID-PATH615〉3.0.CO;2-Z) (Pubitemid 30394896)
10. van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den Meiracker AH, Stijnen TH & Boomsma F 2002 The value of plasma markers for the clinical behaviour of phaeochromocytomas. European Journal of Endocrinology 147 85-94. (doi:10.1016/0046-8177(90)90155-X) (Pubitemid 34814744)
11. Kimura N & Sasano N 1990 A comparative study between malignant and benign pheochromocytoma using morphometry, cytophotometry, and immunohistochemistry. In Endocrine Pathology Update, pp 99-118. Eds J Lechago&T Kameya. New York: Field&Wood Medical Publishers, Inc.
12. Kimura N, Miura Y, Nagatsu I & Nagura H 1992 Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. Virchows Archiv. A, Pathological Anatomy and Histopathology 421 25-32. (doi:10.1007/BF01607135)
13. Kimura N, Watanabe T, Noshiro T, Shizawa S & Miura Y 2005 Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocrine Pathology 16 23-32. (doi:10.1385/EP:16:1:023) (Pubitemid 41278311)
14. King KS & Pacak K 2013 Familial pheochromocytomas and paragangliomas. Molecular and Cellular Endocrinology 386 92-100. (doi:10.1016/j.mce.2013.07. 032)
15. Lack EE 2007 Extraadrenal paraganglia, paragangliomas, and other features of sympathoadrenal paragangnliomas. In Tumours of the Adrenal Glands and Extraadrenal Paraganglia. AFIP Atlas of Tumor Pathology. Fourth Series, Fascicle 8, pp 283-322. Washington DC: AFIP & ARP Press.
16. Linnoila RI, Keiser HR, Steinberg SM & Lack EE 1990 Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Human Pathology 21 1168-1180. (doi:10.1016/0046-8177(90)90155-X) (Pubitemid 20382001)
17. Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T & Omata K 1999 Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Modern Pathology 12 1107-1111. (Pubitemid 30033543)
18. Naruse M & PHEO-J Study Group 2011 Nationwide survey and PHEO network for the study of pheochromocytoma/paraganglioma in Japan (PHEO-J). Endocrine Reviews 32 Meeting Abstracts: P2-631. (doi:10.1210/endo-meetings.2011.32.03- MeetingAbstracts.P2-631P2-631)
19. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Rivière J, Dannenberg H et al. 2009 An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncology 10 764-771. (doi:10.1016/S1470-2045(09)70164-0)
20. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA et al. 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Journal of the American Medical Association 292 943-951. (doi:10.1001/jama.292.8.943) (Pubitemid 39097204)
21. O'Riordain DS, YoungWF Jr, Grant CS, Carney JA & van Heerden JA 1996 Clinical spectrumand outcome of functional extraadrenal paraganglioma. World Journal of Surgery 20 916-921. (doi:10.1007/s002689900139)
22. Thompson LD 2002 Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to separate benign frommalignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. American Journal of Surgical Pathology 26 551-566. (doi:10.1097/00000478-200205000-00002) (Pubitemid 34438716)
23. Thompson LD, Young WF Jr, Kawashima A, Komminoth P & Tischler AS 2004 Malignant adrenal pheochromocytoma. In World Health Organization Classification of Tumours Pathology & Genetics Tumours of Endocrine Organs, pp 147-150. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC.
24. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D, Lenders JW & Pacak K 2007 Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. Journal of Clinical Endocrinology and Metabolism 92 779-786. (doi:10.1210/jc.2006-2315) (Pubitemid 46465640)
25. Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D & Kaneko M 1991 S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Archives of Pathology & Laboratory Medicine 115 484-487.
26. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F & Nosé V 2009 Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. American Journal of Surgical Pathology 33 599-608. (doi:10.1097/PAS.0b013e318190d12e)
27. Zelinka T, Musil Z, Dušková J, Burton D, Merino MJ, Milosevic D, Widimský J Jr & Pacak K 2011 Metastatic pheochromocytoma: does the size and age matter? European Journal of Clinical Investigation 41 1121-1128. (doi:10.1111/j.1365-2362.2011.02518.x)